Fig 3.

In vivo T cell activation and stability of β-Gal expression following intramuscular injection of broad and narrow AAV8-AAVrh32.33 hybrid capsid vectors. (A) C57BL/6 mice were injected i.m. with a dose of 1 × 10¹¹ GCs of either wild-type AAV8 or AAVrh32.33 or the panel of hybrid capsid vectors expressing CB.nLacZ. *, the broad-swap versions of LM10, LM11, and LM12 were injected at a dose of 5 × 10¹⁰ GCs/mouse to compensate for limiting titers. The percentage of nLacZ-specific CD8⁺ T cells present in whole blood was assayed at days 14, 21, and 28 by MHC-I tetramer staining. At day 28, X-Gal histochemistry was performed on muscle sections to monitor for cellular infiltration and the stability of β-Gal expression. Representative images were taken from 4 mice per group. The tetramer stain data represent means ± SDs from 4 mice/group. (B) C57BL/6 mice injected with 5 × 10¹⁰ GCs of AAV2/8.nLacZ, AAV2/rh32.33.nLacZ, or LM10 (AAV2/rh32.33-8_VR.I hybrids) made with either narrow or broad swaps. Representative images were taken from 4 mice per group on day 10 postinjection. Magnifications, ×10.